Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 1,100 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,100 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $45.01, for a total value of $49,511.00. Following the completion of the sale, the director now owns 318,652 shares of the company’s stock, valued at $14,342,526.52. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Pro-Dex Stock Performance

NASDAQ:PDEX opened at $35.30 on Tuesday. The company has a market cap of $115.08 million, a price-to-earnings ratio of 17.56 and a beta of 0.53. Pro-Dex, Inc. has a fifty-two week low of $16.18 and a fifty-two week high of $59.60. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. The stock has a fifty day moving average price of $47.43 and a 200-day moving average price of $34.74.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. As a group, equities analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Hedge Funds Weigh In On Pro-Dex

Institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after buying an additional 529 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after purchasing an additional 900 shares in the last quarter. FMR LLC grew its holdings in shares of Pro-Dex by 34.9% during the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the last quarter. Bard Associates Inc. increased its position in Pro-Dex by 17.6% during the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after purchasing an additional 2,031 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Pro-Dex by 9.1% in the third quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares in the last quarter. Institutional investors and hedge funds own 15.28% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PDEX. Ascendiant Capital Markets upped their price target on shares of Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, November 11th. StockNews.com lowered shares of Pro-Dex from a “strong-buy” rating to a “buy” rating in a research report on Monday.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.